Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:ONCY NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$17.69$19.88$8.72▼$27.41$487.54M1.16244,134 shs119,469 shsONCYOncolytics Biotech$0.96$0.92$0.56▼$1.51$114.58M1.071.70 million shs1.13 million shsORMPOramed Pharmaceuticals$3.88$3.95$1.98▼$5.01$158.81M1.26181,483 shs148,935 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma-2.86%-3.54%-4.27%+62.29%+21.00%ONCYOncolytics Biotech+3.03%+17.07%+23.87%+1.05%+29.73%ORMPOramed Pharmaceuticals+2.37%+2.11%-10.39%+11.17%+80.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$17.69$19.88$8.72▼$27.41$487.54M1.16244,134 shs119,469 shsONCYOncolytics Biotech$0.96$0.92$0.56▼$1.51$114.58M1.071.70 million shs1.13 million shsORMPOramed Pharmaceuticals$3.88$3.95$1.98▼$5.01$158.81M1.26181,483 shs148,935 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma-2.86%-3.54%-4.27%+62.29%+21.00%ONCYOncolytics Biotech+3.03%+17.07%+23.87%+1.05%+29.73%ORMPOramed Pharmaceuticals+2.37%+2.11%-10.39%+11.17%+80.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.00Buy$29.0063.93% UpsideONCYOncolytics Biotech 2.75Moderate Buy$8.50785.42% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ONCY, ORMP, and CBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/29/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/13/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D-)5/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10.84M44.98N/AN/A$14.32 per share1.24ONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/AORMPOramed Pharmaceuticals$2M79.40$0.09 per share41.78$5.02 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%7/30/2026 (Estimated)ONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)ORMPOramed Pharmaceuticals$64.05M$2.591.50N/AN/AN/A-5.37%-4.83%8/13/2026 (Estimated)Latest ONCY, ORMP, and CBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A4/29/2026Q1 2026CBIOCrescent Biopharma-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 million3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.256.44%N/A9.65%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A13.7813.78ONCYOncolytics BiotechN/A1.381.38ORMPOramed PharmaceuticalsN/A6.456.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%ONCYOncolytics Biotech6.82%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma4.00%ONCYOncolytics Biotech0.10%ORMPOramed Pharmaceuticals17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5027.56 million26.46 millionNo DataONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableORMPOramed Pharmaceuticals1040.93 million33.64 millionOptionableONCY, ORMP, and CBIO HeadlinesRecent News About These CompaniesORMP: View inclusion in Russell indexes as positive that could raise awareness in investment communityJune 18 at 3:08 PM | msn.comOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesJune 17 at 8:55 AM | prnewswire.comORMP: Strategically acquiring interests in medtech & technology companiesJune 8, 2026 | msn.comOramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment DirectionMay 22, 2026 | seekingalpha.comOramed Pharmaceuticals Inc.May 18, 2026 | marketwatch.comOramed Pharmaceuticals Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMPMay 15, 2026 | benzinga.comOramed Pharmaceuticals IncorporatedApril 15, 2026 | edition.cnn.comOramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38March 27, 2026 | msn.comOramed: Q4 Earnings SnapshotMarch 26, 2026 | stamfordadvocate.comSLifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with OramedMarch 26, 2026 | finanznachrichten.deLifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to ProfitabilityMarch 13, 2026 | quiverquant.comQLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyMarch 13, 2026 | globenewswire.comOramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | finanznachrichten.deOramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | prnewswire.comLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyJanuary 13, 2026 | globenewswire.comOramed stock rises after receiving $18 million payment from ScilexJanuary 7, 2026 | za.investing.comOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsJanuary 7, 2026 | prnewswire.comOramed Pharm completes warrant sale, boosting liquidityDecember 31, 2025 | msn.comWhy Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Up 7.03%December 25, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, ORMP, and CBIO Company DescriptionsCrescent Biopharma NASDAQ:CBIO$17.69 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$17.66 -0.03 (-0.17%) As of 06/18/2026 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Oncolytics Biotech NASDAQ:ONCY$0.96 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.95 -0.01 (-0.63%) As of 06/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Oramed Pharmaceuticals NASDAQ:ORMP$3.88 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.92 +0.04 (+1.01%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
